109 related articles for article (PubMed ID: 28646023)
1. Amlexanox Downregulates S100A6 to Sensitize
Tamai H; Yamaguchi H; Miyake K; Takatori M; Kitano T; Yamanaka S; Yui S; Fukunaga K; Nakayama K; Inokuchi K
Cancer Res; 2017 Aug; 77(16):4426-4433. PubMed ID: 28646023
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of S100A6 induces GVL effects in MLL/AF4-positive ALL in human PBMC-SCID mice.
Tamai H; Miyake K; Yamaguchi H; Shimada T; Dan K; Inokuchi K
Bone Marrow Transplant; 2014 May; 49(5):699-703. PubMed ID: 24583627
[TBL] [Abstract][Full Text] [Related]
3. Resistance of MLL-AFF1-positive acute lymphoblastic leukemia to tumor necrosis factor-alpha is mediated by S100A6 upregulation.
Tamai H; Miyake K; Yamaguchi H; Takatori M; Dan K; Inokuchi K; Shimada T
Blood Cancer J; 2011 Nov; 1(11):e38. PubMed ID: 22829076
[TBL] [Abstract][Full Text] [Related]
4. HMGA2 as a potential molecular target in KMT2A-AFF1-positive infant acute lymphoblastic leukaemia.
Wu Z; Eguchi-Ishimae M; Yagi C; Iwabuki H; Gao W; Tauchi H; Inukai T; Sugita K; Ishii E; Eguchi M
Br J Haematol; 2015 Dec; 171(5):818-29. PubMed ID: 26403224
[TBL] [Abstract][Full Text] [Related]
5. Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A::AFF1 fusion.
Tretti Parenzan C; Molin AD; Longo G; Gaffo E; Buratin A; Cani A; Boldrin E; Serafin V; Guglielmelli P; Vannucchi AM; Cazzaniga G; Biondi A; Locatelli F; Meyer LH; Buldini B; Te Kronnie G; Bresolin S; Bortoluzzi S
Blood Adv; 2024 Mar; 8(5):1305-1319. PubMed ID: 38029383
[TBL] [Abstract][Full Text] [Related]
6. AAV8 vector expressing IL24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4-positive ALL model mice.
Tamai H; Miyake K; Yamaguchi H; Takatori M; Dan K; Inokuchi K; Shimada T
Blood; 2012 Jan; 119(1):64-71. PubMed ID: 22025528
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin-c is overexpressed in KMT2A-AFF1 positive pediatric B-cell lymphoblastic leukemia when compared to those with ETV6-RUNX1".
da Fonseca Bastos ACS; da Silva Rezende AC; Ferreira LB; Blunck CB; Pombo-de-Oliveira MS; Emerenciano M; Gimba ERP
Leuk Res; 2020 Apr; 91():106316. PubMed ID: 32114371
[No Abstract] [Full Text] [Related]
8. Genetic and Epigenetic Characterization of a Discordant
Russo A; Viberti C; Mareschi K; Casalone E; Guarrera S; Birolo G; Cazzaniga G; Corral L; Trentin L; Basso G; Fagioli F; Matullo G
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575904
[TBL] [Abstract][Full Text] [Related]
9. Generation of a human induced pluripotent stem cell line harboring the infant leukemia-associated fusion gene, KMT2A-AFF1 (IMSUTi002-A-2).
Takahashi M
Stem Cell Res; 2023 Sep; 71():103185. PubMed ID: 37639801
[TBL] [Abstract][Full Text] [Related]
10. Genome editing-induced t(4;11) chromosomal translocations model B cell precursor acute lymphoblastic leukemias with KMT2A-AFF1 fusion.
Pan F; Sarno J; Jeong J; Yang X; Jager A; Gruber TA; Davis KL; Cleary ML
J Clin Invest; 2024 Jan; 134(1):. PubMed ID: 37917159
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.
Loftus JP; Yahiaoui A; Brown PA; Niswander LM; Bagashev A; Wang M; Schauf A; Tannheimer S; Tasian SK
Haematologica; 2021 Apr; 106(4):1067-1078. PubMed ID: 32414848
[TBL] [Abstract][Full Text] [Related]
12. Romidepsin enhances the efficacy of cytarabine
Cheung LC; Cruickshank MN; Hughes AM; Singh S; Chua GA; Ford J; Ferrari E; Oommen J; Malinge S; Lock RB; Kees UR; Kotecha RS
Haematologica; 2019 Jul; 104(7):e300-e303. PubMed ID: 30679330
[No Abstract] [Full Text] [Related]
13. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.
Urtishak KA; Wang LS; Culjkovic-Kraljacic B; Davenport JW; Porazzi P; Vincent TL; Teachey DT; Tasian SK; Moore JS; Seif AE; Jin S; Barrett JS; Robinson BW; Chen IL; Harvey RC; Carroll MP; Carroll AJ; Heerema NA; Devidas M; Dreyer ZE; Hilden JM; Hunger SP; Willman CL; Borden KLB; Felix CA
Oncogene; 2019 Mar; 38(13):2241-2262. PubMed ID: 30478448
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience.
Richard-Carpentier G; Kantarjian HM; Tang G; Yin CC; Khoury JD; Issa GC; Haddad F; Jain N; Ravandi F; Short NJ; DiNardo CD; Takahashi K; Konopleva MY; Daver NG; Kadia T; Garcia-Manero G; Garris R; O'Brien S; Jabbour E
Blood Adv; 2021 Dec; 5(23):5415-5419. PubMed ID: 34525185
[TBL] [Abstract][Full Text] [Related]
15. A KMT2A-AFF1 gene regulatory network highlights the role of core transcription factors and reveals the regulatory logic of key downstream target genes.
Harman JR; Thorne R; Jamilly M; Tapia M; Crump NT; Rice S; Beveridge R; Morrissey E; de Bruijn MFTR; Roberts I; Roy A; Fulga TA; Milne TA
Genome Res; 2021 Jul; 31(7):1159-1173. PubMed ID: 34088716
[TBL] [Abstract][Full Text] [Related]
16. Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia.
Stevanović S; Griffioen M; Nijmeijer BA; van Schie ML; Stumpf AN; Rutten CE; Willemze R; Falkenburg JH
Leukemia; 2012 Feb; 26(2):312-22. PubMed ID: 21860431
[TBL] [Abstract][Full Text] [Related]
17. Up-regulated A20 promotes proliferation, regulates cell cycle progression and induces chemotherapy resistance of acute lymphoblastic leukemia cells.
Chen S; Xing H; Li S; Yu J; Li H; Liu S; Tian Z; Tang K; Rao Q; Wang M; Wang J
Leuk Res; 2015 Sep; 39(9):976-83. PubMed ID: 26159495
[TBL] [Abstract][Full Text] [Related]
18. EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia.
Konantz M; André MC; Ebinger M; Grauer M; Wang H; Grzywna S; Rothfuss OC; Lehle S; Kustikova OS; Salih HR; Handgretinger R; Fend F; Baum C; Kanz L; Quintanilla-Martinez L; Schulze-Osthoff K; Essmann F; Lengerke C
Leukemia; 2013 Jan; 27(1):56-65. PubMed ID: 22828445
[TBL] [Abstract][Full Text] [Related]
19. Discovery of fusion circular RNAs in leukemia with KMT2A::AFF1 rearrangements by the new software CircFusion.
Dal Molin A; Tretti Parenzan C; Gaffo E; Borin C; Boldrin E; Meyer LH; Te Kronnie G; Bresolin S; Bortoluzzi S
Brief Bioinform; 2023 Jan; 24(1):. PubMed ID: 36585787
[TBL] [Abstract][Full Text] [Related]
20. An AF9/ENL-targted peptide with therapeutic potential in mixed lineage leukemias.
Barretto NN; Karahalios DS; You D; Hemenway CS
J Exp Ther Oncol; 2014; 10(4):293-300. PubMed ID: 25509985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
